fasudil has been researched along with Ureteral Obstruction in 3 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Ureteral Obstruction: Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to investigate possible effects of the Rho-kinase inhibitor, fasudil, on the progression of renal failure in rats with unilateral ureteral obstruction." | 7.71 | Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. ( Asano, T; Hitomi, A; Ikegaki, I; Sato, N; Satoh, S; Shimokawa, H; Shiraiwa, K; Yamaguchi, T, 2002) |
| "Renal fibrosis is the major cause of chronic kidney disease, and the Rho/Rho-associated coiled-coil kinase (ROCK) signaling cascade is involved in the renal fibrotic processes." | 5.42 | Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction. ( Baba, I; Egi, Y; Kakimoto, T; Suzuki, K; Utsumi, H, 2015) |
| " This study was designed to compare the effects of an angiotensin-converting enzyme (ACE) inhibitor (imidapril), a Rho-kinase inhibitor (fasudil) and a combination of them both on renal interstitial fibrosis induced by unilateral ureteral obstruction (UUO)." | 3.76 | Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction. ( Akimoto, K; Ishimitsu, T; Matsuoka, H; Nishikimi, T; Takeda, Y, 2010) |
| "This study was designed to investigate possible effects of the Rho-kinase inhibitor, fasudil, on the progression of renal failure in rats with unilateral ureteral obstruction." | 3.71 | Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. ( Asano, T; Hitomi, A; Ikegaki, I; Sato, N; Satoh, S; Shimokawa, H; Shiraiwa, K; Yamaguchi, T, 2002) |
| "Renal fibrosis is the major cause of chronic kidney disease, and the Rho/Rho-associated coiled-coil kinase (ROCK) signaling cascade is involved in the renal fibrotic processes." | 1.42 | Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction. ( Baba, I; Egi, Y; Kakimoto, T; Suzuki, K; Utsumi, H, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baba, I | 1 |
| Egi, Y | 1 |
| Utsumi, H | 1 |
| Kakimoto, T | 1 |
| Suzuki, K | 1 |
| Takeda, Y | 1 |
| Nishikimi, T | 1 |
| Akimoto, K | 1 |
| Matsuoka, H | 1 |
| Ishimitsu, T | 1 |
| Satoh, S | 1 |
| Yamaguchi, T | 1 |
| Hitomi, A | 1 |
| Sato, N | 1 |
| Shiraiwa, K | 1 |
| Ikegaki, I | 1 |
| Asano, T | 1 |
| Shimokawa, H | 1 |
3 other studies available for fasudil and Ureteral Obstruction
| Article | Year |
|---|---|
Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Cell Line; Cell Movement; Collagen T | 2015 |
Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Angiotensin-Converting Enzyme Inhibitors; Ani | 2010 |
Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Chemotaxis; Dose-Response Relationship, Drug | 2002 |